Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $1.72 in the prior trading day, Inozyme Pharma Inc (NASDAQ: INZY) closed at $1.51, down -12.21%. In other words, the price has decreased by -$12.21 from its previous closing price. On the day, 1.54 million shares were traded. INZY stock price reached its highest trading level at $1.77 during the session, while it also had its lowest trading level at $1.45.
Ratios:
Our goal is to gain a better understanding of INZY by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.68 and its Current Ratio is at 7.68. In the meantime, Its Debt-to-Equity ratio is 0.57 whereas as Long-Term Debt/Eq ratio is at 0.51.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Raymond James on December 12, 2024, initiated with a Outperform rating and assigned the stock a target price of $26.
On September 12, 2024, Stifel started tracking the stock assigning a Buy rating and target price of $16.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 02 ’24 when Treco Douglas A sold 7,523 shares for $6.94 per share. The transaction valued at 52,210 led to the insider holds 20,665 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INZY now has a Market Capitalization of 97002704 and an Enterprise Value of 12186699.
Stock Price History:
The Beta on a monthly basis for INZY is 1.41, which has changed by -0.5952941 over the last 52 weeks, in comparison to a change of 0.23147523 over the same period for the S&P500. Over the past 52 weeks, INZY has reached a high of $7.80, while it has fallen to a 52-week low of $1.61. The 50-Day Moving Average of the stock is -50.18%, while the 200-Day Moving Average is calculated to be -66.75%.
Shares Statistics:
The stock has traded on average 581.51K shares per day over the past 3-months and 748620 shares per day over the last 10 days, according to various share statistics. A total of 64.18M shares are outstanding, with a floating share count of 43.99M. Insiders hold about 31.52% of the company’s shares, while institutions hold 65.09% stake in the company. Shares short for INZY as of 1735603200 were 3701002 with a Short Ratio of 6.36, compared to 1732838400 on 3407026. Therefore, it implies a Short% of Shares Outstanding of 3701002 and a Short% of Float of 6.23.
Earnings Estimates
The current rating of Inozyme Pharma Inc (INZY) reflects the combined expertise of 3.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$1.5 and -$1.52 for the fiscal current year, implying an average EPS of -$1.51. EPS for the following year is -$1.5, with 3.0 analysts recommending between -$1.33 and -$1.67.
